What Pegasys Treats
Pegasys (peginterferon alfa-2a) is an injectable antiviral medication primarily used to treat chronic hepatitis C virus (HCV) infection in adults and children aged 5 years and older. It works by boosting the immune response to fight the virus, often combined with ribavirin or other direct-acting antivirals.[1]
How It's Used for Hepatitis B
Pegasys also treats chronic hepatitis B virus (HBV) in adults with evidence of viral replication and liver inflammation. It's administered as a weekly subcutaneous injection for 48 weeks, aiming to suppress viral replication and prevent liver damage progression.[1][2]
Role in Other Conditions
In combination regimens, Pegasys addresses certain HIV/HCV co-infections. It's not a first-line therapy today due to newer oral antivirals but remains relevant in specific resistant cases or resource-limited settings.[1]
Common Side Effects Patients Report
Fatigue, flu-like symptoms (fever, chills, muscle aches), depression, anemia, and injection-site reactions occur frequently. Serious risks include neuropsychiatric effects, autoimmune disorders, and thyroid issues—monitoring is required.[1][2]
Who Makes Pegasys and Availability
Genentech (a Roche subsidiary) manufactures Pegasys. It's available as a prefilled syringe or vial. Use has declined with direct-acting antivirals like sofosbuvir, but it's still prescribed where needed.[1]
Patent Status and Generics
Pegasys patents have largely expired in major markets (e.g., U.S. composition patent ended around 2014-2016). No true generics exist due to its biologic nature, but biosimilar challenges are ongoing. Check DrugPatentWatch.com for latest expiry details and litigation.[3]
[1] Pegasys Prescribing Information, Genentech (FDA-approved label).
[2] NIH Hepatitis Treatment Guidelines.
[3] DrugPatentWatch.com - Pegasys.